Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy
出版年份 2021 全文链接
标题
Progress in the development of small molecular inhibitors of the Bruton’s tyrosine kinase (BTK) as a promising cancer therapy
作者
关键词
Bruton tyrosine kinase, Anticancer activity, Inhibitors, PROTAC
出版物
BIOORGANIC & MEDICINAL CHEMISTRY
Volume 47, Issue -, Pages 116358
出版商
Elsevier BV
发表日期
2021-08-10
DOI
10.1016/j.bmc.2021.116358
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies
- (2021) Wanxiao Sun et al. JOURNAL OF CONTROLLED RELEASE
- Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
- (2021) William Farnaby et al. CURRENT OPINION IN PHARMACOLOGY
- Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy
- (2021) Xiao-Jing Pang et al. MOLECULES
- Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib
- (2020) Clare CHUI LING Sun et al. BLOOD
- Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
- (2020) Sabrina Dallavalle et al. DRUG RESISTANCE UPDATES
- Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
- (2020) Tingting Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs
- (2020) Ronen Gabizon et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Discovery of quinoline-based irreversible BTK inhibitors
- (2020) Gerjan de Bruin et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Discovery of potent and highly selective covalent inhibitors of Bruton’s tyrosine kinase bearing triazine scaffold
- (2020) Yu Teng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Characterization of a dual BET / HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma
- (2020) Xin Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date
- (2020) Yazeed Sawalha et al. OncoTargets and Therapy
- Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the Hippo signaling pathway
- (2020) Jian Song et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)
- (2020) Yang Lu et al. JOURNAL OF MEDICINAL CHEMISTRY
- HZ-A-005, a potent, selective, and covalent Bruton’s tyrosine kinase inhibitor in preclinical development
- (2020) Wenhai Huang et al. BIOORGANIC CHEMISTRY
- Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML
- (2020) Si Li et al. BIOORGANIC CHEMISTRY
- Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
- (2020) Shenxin Zeng et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of novel chalcone-dithiocarbamates as ROS-mediated apoptosis inducers by inhibiting catalase
- (2019) Dong-Jun Fu et al. BIOORGANIC CHEMISTRY
- Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas
- (2019) Yonghui Sun et al. LEUKEMIA
- PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding
- (2019) Christopher P. Tinworth et al. ACS Chemical Biology
- Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management
- (2019) Preetesh Jain et al. AMERICAN JOURNAL OF HEMATOLOGY
- Discovery of pyrazolopyrimidine derivatives as potent BTK inhibitors with effective anticancer activity in MCL
- (2019) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- Genetic alterations and their clinical implications in DLBCL
- (2019) Yi Miao et al. Nature Reviews Clinical Oncology
- Structural mechanism for Bruton’s tyrosine kinase activation at the cell membrane
- (2019) Qi Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting BTK in CLL: Beyond Ibrutinib
- (2019) David A. Bond et al. Current Hematologic Malignancy Reports
- Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors
- (2019) Meng-zhen Lai et al. ACTA PHARMACOLOGICA SINICA
- Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors
- (2019) Zheng Zhai et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Some new anticancer platinum complexes of dithiocarbamate derivatives against human colorectal and pancreatic cell lines
- (2019) Soudeh Hosseinzadeh et al. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
- Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton’s tyrosine kinase inhibitors
- (2019) Yanyan Diao et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies
- (2019) Allard Kaptein et al. Clinical Lymphoma Myeloma & Leukemia
- Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines
- (2019) Xiaofeng Guo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
- (2019) Xiaotian Kong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase
- (2019) Yunhang Guo et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
- (2019) Richard D. Caldwell et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors
- (2019) Jing Ren et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Discovery of 1,2,4-triazine-based derivatives as novel neddylation inhibitors and anticancer activity studies against gastric cancer MGC-803 cells
- (2019) Jian Song et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and synthesis of novel 1-substituted 3-(6-phenoxypyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine analogs as selective BTK inhibitors for the treatment of mantle cell lymphoma
- (2019) Fansheng Ran et al. BIOORGANIC CHEMISTRY
- New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia
- (2019) Jeanluc Bertrand et al. BIOORGANIC CHEMISTRY
- Combination of Gatekeeper Mutations and Cysteine 481 Replacement Causes Super Resistance to the Irreversible BTK Inhibitors Ibrutinib, Acalabrutinib and Zanubrutinib
- (2019) Hernando Yesid Estupiñan Velasquez et al. BLOOD
- Final Results of Phase 1, Dose Escalation Study Evaluating ARQ 531 in Patients with Relapsed or Refractory B-Cell Lymphoid Malignancies
- (2019) Jennifer Woyach et al. BLOOD
- Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties
- (2019) Saul Jaime-Figueroa et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation
- (2018) Alexandru D. Buhimschi et al. BIOCHEMISTRY
- Design, synthesis and biological evaluation of novel 3-substituted pyrazolopyrimidine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors
- (2018) Nan Zheng et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines
- (2018) Changyuan Wang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
- (2018) Yonghui Sun et al. CELL RESEARCH
- Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R
- (2018) Yu Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma
- (2018) Yang Ge et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Predicting the Conformational Variability of Abl Tyrosine Kinase using Molecular Dynamics Simulations and Markov State Models
- (2018) Yilin Meng et al. Journal of Chemical Theory and Computation
- Role of Bruton’s tyrosine kinase in B cells and malignancies
- (2018) Simar Pal Singh et al. Molecular Cancer
- Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors
- (2018) Haiyang Chen et al. MedChemComm
- Design and synthesis of benzofuro[3,2-b]pyridin-2(1H)-one derivatives as anti-leukemia agents by inhibiting Btk and PI3Kδ
- (2018) Linyi Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Conversion of carbazole carboxamide based reversible inhibitors of Bruton’s tyrosine kinase (BTK) into potent, selective irreversible inhibitors in the carbazole, tetrahydrocarbazole, and a new 2,3-dimethylindole series
- (2018) Qingjie Liu et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Identification of metabolites of evobrutinib in rat and human hepatocytes by using ultra-high performance liquid chromatography coupled with diode array detector and Q Exactive Orbitrap tandem mass spectrometry
- (2018) Zeyun Li et al. Drug Testing and Analysis
- The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
- (2018) Sean D. Reiff et al. Cancer Discovery
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- Targeting Bruton’s Tyrosine Kinase Across B-Cell Malignancies
- (2018) Caspar da Cunha-Bang et al. DRUGS
- Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia
- (2018) Eriong Lee-Vergés et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of 5,6-diaryl-1,2,4-triazines hybrids as potential apoptosis inducers
- (2017) Dong-Jun Fu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of formononetin-dithiocarbamate hybrids that inhibit growth and migration of PC-3 cells via MAPK/Wnt signaling pathways
- (2017) Dong-Jun Fu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines
- (2017) Dan Zhao et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia
- (2017) He Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Bruton’s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL)
- (2017) Philip A Thompson et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling
- (2017) Andrew T. Bender et al. MOLECULAR PHARMACOLOGY
- Discovery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties
- (2017) Xiaojing Wang et al. ACS Medicinal Chemistry Letters
- Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
- (2017) Alexander N. R. Weber et al. Frontiers in Immunology
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- (2016) Adam R. Johnson et al. ACS Chemical Biology
- Chronic lymphocytic leukemia (CLL)-Then and now
- (2016) Kanti R. Rai et al. AMERICAN JOURNAL OF HEMATOLOGY
- Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors
- (2016) Zhendong Song et al. BIOORGANIC & MEDICINAL CHEMISTRY
- The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
- (2016) Sarah E.M. Herman et al. CLINICAL CANCER RESEARCH
- Targeting Ibrutinib-Resistant BTK-C481S Mutation with ARQ 531, a Reversible Non-Covalent Inhibitor of BTK
- (2016) Sudharshan Eathiraj et al. Clinical Lymphoma Myeloma & Leukemia
- Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors
- (2016) Sahil Sharma et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
- (2016) J. R. Brown et al. HAEMATOLOGICA
- Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Second-generation inhibitors of Bruton tyrosine kinase
- (2016) Jingjing Wu et al. Journal of Hematology & Oncology
- Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside
- (2016) Jingjing Wu et al. Oncotarget
- Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia
- (2016) J. R. Brown et al. HAEMATOLOGICA
- Abstract C186: SNS-062 is a potent noncovalent BTK inhibitor with comparable activity against wild type BTK and BTK with an acquired resistance mutation
- (2015) Minke E. Binnerts et al. MOLECULAR CANCER THERAPEUTICS
- Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma
- (2014) Hong Wu et al. ACS Chemical Biology
- Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases
- (2014) Qing Shi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Identification of novel PTP1B inhibitors by pharmacophore based virtual screening, scaffold hopping and docking
- (2014) Vishal M. Balaramnavar et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases
- (2014) Zilan Song et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Series of 2,5-Diaminopyrimidine Covalent Irreversible Inhibitors of Bruton’s Tyrosine Kinase with in Vivo Antitumor Activity
- (2014) Xitao Li et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
- (2014) Jan A Burger et al. LANCET ONCOLOGY
- Ibrutinib and novel BTK inhibitors in clinical development
- (2013) Akintunde Akinleye et al. Journal of Hematology & Oncology
- Fragment-Based Discovery of New Highly Substituted 1H-Pyrrolo[2,3-b]- and 3H-Imidazolo[4,5-b]-Pyridines as Focal Adhesion Kinase Inhibitors
- (2013) Timo Heinrich et al. JOURNAL OF MEDICINAL CHEMISTRY
- 1,3,5-Triazine as a Modular Scaffold for Covalent Inhibitors with Streamlined Target Identification
- (2013) Ranjan Banerjee et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
- (2013) A. O. Walter et al. Cancer Discovery
- Design, synthesis and CoMFA studies of N1-amino acid substituted 2,4,5-triphenyl imidazoline derivatives as p53–MDM2 binding inhibitors
- (2012) Chunqi Hu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- BMX and Its Role in Inflammation, Cardiovascular Disease, and Cancer
- (2012) Bruno Cenni et al. INTERNATIONAL REVIEWS OF IMMUNOLOGY
- The resurgence of covalent drugs
- (2011) Juswinder Singh et al. NATURE REVIEWS DRUG DISCOVERY
- The Src, Syk, and Tec family kinases: Distinct types of molecular switches
- (2010) J. Michael Bradshaw CELLULAR SIGNALLING
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- Identification ofN,1,4,4-Tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a Potent, Orally Available Cyclin Dependent Kinase Inhibitor
- (2009) Maria Gabriella Brasca et al. JOURNAL OF MEDICINAL CHEMISTRY
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
- (2009) Wenjun Zhou et al. NATURE
- Novel N9-arenethenyl purines as potent dual Src/Abl tyrosine kinase inhibitors
- (2008) Yihan Wang et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
- (2008) S. Giordano et al. CURRENT MEDICINAL CHEMISTRY
- Multiple Colorectal Neoplasms in X-Linked Agammaglobulinemia
- (2007) Lodewijk A.A. Brosens et al. Clinical Gastroenterology and Hepatology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started